NEWS & MEDIA

Axiogenesis In-Licenses Yamanaka Patent Portfolio from iPS Academia Japan Covering Induced Pluripotent Stem Cell Technology 
 

August 2010 – COLOGNE, Germany - Axiogenesis AG and iPS Academia Japan Inc. (Kyoto, Japan) announced that they have executed a non-exclusive agreement through which Axiogenesis obtains worldwide access to the extensive portfolio of induced pluripotent stem cell (“iPSC”) technology pioneered by Professor Shinya Yamanaka, to produce iPSC-derived cardiomyocytes and other cell types. See the Press release here.

Axiogenesis AG in Nature: Burgeoning stem cell product market lures major suppliers  
 

June 2010 – Nature Biotechnology: Life sciences supplier Lonza has struck a deal with Axiogenesis of Cologne, Germany, to offer mouse embryonic stem cell–derived cardiomyocytes in its product catalogue. The agreement, signed in March, is the latest move of several large reagent and material suppliers to grab a slice of the rapidly expanding market for stem cell products for use in in vitro assays and testing kits for predictive toxicology...  Find the article here.

Visit us at these upcoming Conferences:  

Elrig Drug Discovery Conference, Ricoh Arena, Coventry, UK, September 1-2 2010

SPS Safety Pharmacology Society, Boston, Massachusetts, September 20-23 2010

Mip Tec, Basel, Switzerland, September 20-24 2010